



PRESS RELEASE

- Update to the corporate events calendar

Capua, 15 September 2017 – Following the release of the press releases published by Pierrel S.p.A. (“Pierrel” or “the Company”) on 26 January 2017, 4 April 2017, 27 April 2017, 30 May 2017, 1 June 2017, 30 June 2017, 14 July 2017, 7 August 2017 and 9 August (available on the Company’s website at www.pierrelgroup.com, section Press/Press Release), also pursuant to Article 2.6.2 of the Regulations of Borsa Italiana S.p.A., the Company announces that:

- (i) Pierrel’s Board of Directors meeting for the approval: (a) of Pierrel’s draft financial statements for the year ended on 31 December 2016; (b) on a voluntary basis, Pierrel Group’s interim report at 31 March 2017; and (c) of the consolidated financial statements at 30 June 2017, will be held on a date to be scheduled between 25 and 29 September 2017;
- (ii) the Shareholders’ Meeting of the Company for the approval of the financial statement closed at 31 December 2016 shall be held on a date to be scheduled between 25 October and 1 November 2017.

The precise date of Directors and shareholders meetings, as well as possible changes to the above, will be communicated to the market and to the regulatory authorities in the timeframe and in the manner required by law and applicable regulations.

Pierrel S.p.A. specialises in the manufacture of pharmaceutical specialty products (*Contract Manufacturing Division*) and the development, registration and licensing of new drugs and medical devices (*Pharma Division*). The Pierrel Group is listed on the MTA exchange organised and managed by Borsa Italiana, and has over 60 years’ experience in the pharmaceutical sector, as one of Europe’s leading producers of local and dental anaesthetics.

Pierrel owns a production unit in Capua, near Naples, Italy, which has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.

The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, the US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy

For further information:

Pierrel S.p.A.

Investor Relations

Fulvio Citaredo

E-mail: investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult S.r.l.

Media Relations

Rossana Del Forno

E-mail: areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665